It has been shown that low-dose VEGF and/or VEGF receptor antiangiogenic therapy can induce tumor vascular normalization, reduce hypoxia, promote tumor CD8+ T lymphocyte infiltration, and enhance tumor immunotherapy [41]. The gene discussed is VEGFA; the disease is neoplasm.